At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Laboratory Biomarker Analysis for Recurrent Transformed B-Cell Non-Hodgkin Lymphoma and Refractory Transformed B-Cell Non-Hodgkin Lymphoma. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This pilot phase II trial studies ibrutinib in treating patients with transformed indolent (a type of cancer that grows slowly) B-cell non-Hodgkin lymphoma that have returned after a period of improvement (relapsed) or do not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes (proteins) needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
CountriesUnited States
CollaboratorsJanssen Pharmaceuticals
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartOct 2014
Primary CompletionNov 2023
TodayJul 2026
First PostedAug 1, 2014
Enrollment StartOct 1, 2014
Primary CompletionNov 1, 2023
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 11.9 years ago
Interventions
Ibrutinibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies